530199 Stock Overview
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally.
Themis Medicare Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹882.15|
|52 Week High||₹1,198.80|
|52 Week Low||₹486.95|
|1 Month Change||-5.75%|
|3 Month Change||-17.83%|
|1 Year Change||78.39%|
|3 Year Change||239.22%|
|5 Year Change||66.33%|
|Change since IPO||3,918.91%|
Recent News & Updates
|530199||IN Pharmaceuticals||IN Market|
Return vs Industry: 530199 exceeded the Indian Pharmaceuticals industry which returned -9.6% over the past year.
Return vs Market: 530199 exceeded the Indian Market which returned 9.6% over the past year.
|530199 Average Weekly Movement||5.5%|
|Pharmaceuticals Industry Average Movement||7.0%|
|Market Average Movement||7.3%|
|10% most volatile stocks in IN Market||10.0%|
|10% least volatile stocks in IN Market||4.8%|
Stable Share Price: 530199 is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: 530199's weekly volatility (5%) has been stable over the past year.
About the Company
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, including anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001.
Themis Medicare Fundamentals Summary
|530199 fundamental statistics|
Is 530199 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|530199 income statement (TTM)|
|Cost of Revenue||₹1.44b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
May 30, 2022
|Earnings per share (EPS)||77.15|
|Net Profit Margin||18.85%|
How did 530199 perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is Themis Medicare undervalued compared to its fair value and its price relative to the market?
Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 530199 (₹882.15) is trading below our estimate of fair value (₹1085.52)
Significantly Below Fair Value: 530199 is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: 530199 is good value based on its PE Ratio (11.4x) compared to the Indian Pharmaceuticals industry average (21.9x).
PE vs Market: 530199 is good value based on its PE Ratio (11.4x) compared to the Indian market (20.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 530199's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 530199 is overvalued based on its PB Ratio (3.1x) compared to the IN Pharmaceuticals industry average (2.6x).
How is Themis Medicare forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Themis Medicare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Themis Medicare performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 530199 has high quality earnings.
Growing Profit Margin: 530199's current net profit margins (18.8%) are higher than last year (16.2%).
Past Earnings Growth Analysis
Earnings Trend: 530199's earnings have grown significantly by 41.5% per year over the past 5 years.
Accelerating Growth: 530199's earnings growth over the past year (103.2%) exceeds its 5-year average (41.5% per year).
Earnings vs Industry: 530199 earnings growth over the past year (103.2%) exceeded the Pharmaceuticals industry 12.4%.
Return on Equity
High ROE: 530199's Return on Equity (26.8%) is considered high.
How is Themis Medicare's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 530199's short term assets (₹2.1B) exceed its short term liabilities (₹1.1B).
Long Term Liabilities: 530199's short term assets (₹2.1B) exceed its long term liabilities (₹260.6M).
Debt to Equity History and Analysis
Debt Level: 530199's net debt to equity ratio (15.5%) is considered satisfactory.
Reducing Debt: 530199's debt to equity ratio has reduced from 89.4% to 25.2% over the past 5 years.
Debt Coverage: 530199's debt is well covered by operating cash flow (85.3%).
Interest Coverage: 530199's interest payments on its debt are well covered by EBIT (14.4x coverage).
What is Themis Medicare current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 530199's dividend (0.49%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).
High Dividend: 530199's dividend (0.49%) is low compared to the top 25% of dividend payers in the Indian market (1.59%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 530199 has been paying a dividend for less than 10 years.
Growing Dividend: 530199's dividend payments have increased, but the company has only paid a dividend for 2 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (5.6%), 530199's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (10%), 530199's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sachin Patel (46 yo)
Dr. Sachin Dinesh Patel, Ph D., CChem. has been Chief Executive Officer and Managing Director of Themis Medicare Limited since February 14, 2017.He served as Deputy Managing Director at Themis Medicare Lt...
CEO Compensation Analysis
Compensation vs Market: Sachin's total compensation ($USD86.15K) is above average for companies of similar size in the Indian market ($USD38.72K).
Compensation vs Earnings: Sachin's compensation has been consistent with company performance over the past year.
Experienced Management: 530199's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: 530199's board of directors are considered experienced (8.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Themis Medicare Limited's employee growth, exchange listings and data sources
- Name: Themis Medicare Limited
- Ticker: 530199
- Exchange: BSE
- Founded: 1969
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹8.116b
- Shares outstanding: 9.20m
- Website: https://www.themismedicare.com
Number of Employees
- Themis Medicare Limited
- 11/12 Udyog Nagar Industrial Estate
- S. V. Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.